Literature DB >> 19226137

Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor.

Ruchi Anand1, Jasna Maksimoska, Nicholas Pagano, Eric Y Wong, Phyllis A Gimotty, Scott L Diamond, Eric Meggers, Ronen Marmorstein.   

Abstract

Mammalian sterile 20 (MST1) kinase, a member of the sterile 20 (Ste-20) family of proteins, is a proapoptotic cytosolic kinase that plays an important role in the cellular response to oxidative stress. In this study, we report on the development of a potent and selective MST1 kinase inhibitor based on a ruthenium half-sandwich scaffold. We show that the enantiopure organoruthenium inhibitor, 9E1, has an IC50 value of 45 nM for MST1 and a greater than 25-fold inhibitor selectivity over the related Ste-20 kinases, p21 activated kinase 1 (PAK1), and p21 activated kinase 4 (PAK4) and an almost 10-fold selectivity over the related thousand-and-one amino acids kinase 2 (TAO2). Compound 9E1 also displays a promising selectivity profile against unrelated protein kinases; however, the proto-oncogene serine/threonine protein kinase PIM1 (PIM-1) and glycogen synthase kinase 3 (GSK-3beta) are inhibited with IC50 values in the low nanomolar range. We also show that 9E1 can inhibit MST1 function in cells. A cocrystal structure of a related compound with PIM-1 and a homology model with MST1 reveals the binding mode of this scaffold to MST1 and provides a starting point for the development of improved MST1 kinase inhibitors for possible therapeutic application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226137      PMCID: PMC2708071          DOI: 10.1021/jm8005806

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

Review 2.  FoxO proteins in insulin action and metabolism.

Authors:  Andreas Barthel; Dieter Schmoll; Terry G Unterman
Journal:  Trends Endocrinol Metab       Date:  2005 May-Jun       Impact factor: 12.015

3.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors.

Authors:  Howard Bregman; Patrick J Carroll; Eric Meggers
Journal:  J Am Chem Soc       Date:  2006-01-25       Impact factor: 15.419

4.  Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.

Authors:  G Ekin Atilla-Gokcumen; Douglas S Williams; Howard Bregman; Nicholas Pagano; Eric Meggers
Journal:  Chembiochem       Date:  2006-09       Impact factor: 3.164

5.  Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety.

Authors:  Howard Bregman; Eric Meggers
Journal:  Org Lett       Date:  2006-11-23       Impact factor: 6.005

Review 6.  The GCK II and III subfamilies of the STE20 group kinases.

Authors:  Celia María Pombo; Thomas Force; John Kyriakis; Emilio Nogueira; Miguel Fidalgo; Juan Zalvide
Journal:  Front Biosci       Date:  2007-01-01

7.  Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Authors:  Peng Xie; Douglas S Williams; G Ekin Atilla-Gokcumen; Leslie Milk; Min Xiao; Keiran S M Smalley; Meenhard Herlyn; Eric Meggers; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2008-05-16       Impact factor: 5.100

8.  FOXO transcription factors: key regulators of cell fate.

Authors:  E W-F Lam; R E Francis; M Petkovic
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

9.  Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.

Authors:  Jeyanthy Eswaran; Wen Hwa Lee; Judit E Debreczeni; Panagis Filippakopoulos; Andrew Turnbull; Oleg Fedorov; Sean W Deacon; Jeffrey R Peterson; Stefan Knapp
Journal:  Structure       Date:  2007-02       Impact factor: 5.006

10.  Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK.

Authors:  Catherine Barthélémy; Christopher E Henderson; Brigitte Pettmann
Journal:  BMC Neurosci       Date:  2004-11-29       Impact factor: 3.288

View more
  20 in total

Review 1.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.

Authors:  Randy Johnson; Georg Halder
Journal:  Nat Rev Drug Discov       Date:  2013-12-13       Impact factor: 84.694

2.  The Hippo Pathway Maintains the Equatorial Division Plane in the Ciliate Tetrahymena.

Authors:  Yu-Yang Jiang; Wolfgang Maier; Ralf Baumeister; Gregory Minevich; Ewa Joachimiak; Zheng Ruan; Natarajan Kannan; Diamond Clarke; Joseph Frankel; Jacek Gaertig
Journal:  Genetics       Date:  2017-04-16       Impact factor: 4.562

3.  A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.

Authors:  Chunle Zhao; Jun Gong; Yu Bai; Taoyuan Yin; Min Zhou; Shutao Pan; Yuhui Liu; Yang Gao; Zhenxiong Zhang; Yongkang Shi; Feng Zhu; Hang Zhang; Min Wang; Renyi Qin
Journal:  Cell Death Differ       Date:  2022-07-29       Impact factor: 12.067

Review 4.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

5.  Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity.

Authors:  Lukas K Filak; Gerhard Mühlgassner; Felix Bacher; Alexander Roller; Markus Galanski; Michael A Jakupec; Bernhard K Keppler; Vladimir B Arion
Journal:  Organometallics       Date:  2010-12-27       Impact factor: 3.876

Review 6.  Beclin 1 biology and its role in heart disease.

Authors:  Hongxin Zhu; Lin He
Journal:  Curr Cardiol Rev       Date:  2015

7.  Development of organometallic S6K1 inhibitors.

Authors:  Jie Qin; Rajathees Rajaratnam; Li Feng; Jemilat Salami; Julie S Barber-Rotenberg; John Domsic; Patricia Reyes-Uribe; Haiying Liu; Weiwei Dang; Shelley L Berger; Jessie Villanueva; Eric Meggers; Ronen Marmorstein
Journal:  J Med Chem       Date:  2014-11-13       Impact factor: 7.446

Review 8.  Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.

Authors:  Sébastien Deslandes; Stefan Chassaing; Evelyne Delfourne
Journal:  Mar Drugs       Date:  2009-12-01       Impact factor: 5.118

9.  Inhibition of mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 2 (Cdk2) by platinum(II) phenanthroline complexes.

Authors:  Emma S Child; Savvas N Georgiades; Kirsten N Rose; Verity S Stafford; Chirag B K Patel; Joachim H G Steinke; David J Mann; Ramon Vilar
Journal:  J Chem Biol       Date:  2011-02-26

Review 10.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.